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Objective: Induction chemoradiotherapy followed by surgery may improve 
survival rates among patients with esophageal carcinoma. We designed anovel 
intense induction regimen with paclitaxel and high-dose hyperfractionated 
radiotherapy to maximize complete response rates. Methods: Forty patients 
with esophageal cancer were treated in a phase I and II trial of induction 
chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels 
(75, 125, and 100 mg/m 2) and concurrent hyperfractionated radiotherapy (45 
Gy to the mediastinum, 58.5 Gy to the tumor). The mean age was 62 years, and 
32 patients(80%) had adenocarcinoma. Twenty-eight of 40 (70%) patients had 
locally advanced tumors (T3, or stage IIB or greater). Results: The average 
hospitalization for induction treatment was 17 days. Toxicity was substantial, 
with esophagitis necessitating nutritional support he most common compli- 
cation. The maximum tolerated ose of paclitaxel was 100 mg/m 2. Two patients 
died during induction treatment. Thirty-six patients (90%) underwent resec- 
tion. The median length of stay was 10 days, and two patients died after the 
operation. Fourteen of 36 patients (39%) had a pathologic omplete response. 
Patients who received all prescribed chemotherapy had a higher pathologic 
complete response rate (50%) than did patients who required dose reduction 
(17%; p = 0.076). The 2-year survival rate was 61% (95% C135% to 86%) with 
a median follow-up of 11.9 months. Conclusions: Paclitaxel at a dose of 100 
mg/m 2 appears to have acceptable toxicity. The high pathologic omplete 
response rate in this regimen is encouraging, but it is associated with 
substantial toxicity. The toxicity of this regimen is not acceptable and will 
require substantial reduction in the radiation component. Survival data are 
too short-term to confirm enhanced survival. (J Thorac Cardiovasc Surg 1997; 
114:811-6) 
M ultimodal therapy of esophageal carcinoma p- 
pears to increase survival. The addition of 
chemotherapy (cisplatin and 5-fluorouracil) to radi- 
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ation therapy increased survival compared with radia- 
tion alone in a randomized trial reported by Herskovic 
and colleagues} Walsh and associates 2 recently re- 
ported that multimodal therapy (cisplatin, 5-fluoro- 
uracil, and radiation therapy) followed by surgical 
resection improves survival compared with surgical 
treatment alone. The optimal regimen remains un- 
known. Previous reports emphasize the importance of 
a high pathologic complete response rate, because 
patients with high rates have enhanced survival 
rates}' 3 Paclitaxel is a new agent with high response 
rates in metastatic esophageal cancer, and it can also 
act as a radiation sensitizer. 4' s We designed an inten- 
sive induction program that included paclitaxel and 
high-dose hyperfractionated radiotherapy in an effort 
to maximize pathologic omplete response rates, po- 
tentially improving survival rates. 
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C isp la t in  C C C C C R S 
5-FU F F F F F 
Pac l i taxe l  T 
XRT V V V V 
V V V V 
C =c isp la t in  20mg/m2/d  
5-FU =5-F luoroura¢ i l  800 mg/m2/d by cont inuous  in fus ion  
P =Pac l i taxe l  per schema given over  3 hours 
=XRT (pre-op dose = 58.5Gy to tumor; 45 to e lec t ive  volulne) 
R =Restag ing  
S =Surgery  
Pgc l i taxe l  Dose Esca la t ion  
Level Dose (mg/m2} 
1 75 
2 125 
3 100 
Fig. 1, Treatment schema. 
Patients and methods 
Patient population. From April 1995 to February 1997. 
77 patients were seen at the Massachusetts General 
Hospital Thoracic Oncology Center with newly diagnosed 
esophageal cancer. All patients with potentially resectable 
esophageal cancer were encouraged to enter this phase I
and II trial of multimodal therapy. Eligibility criteria 
included resectable sophageal cancer, T1 through T4 
disease. NO through N1 disease, bilirubin level of 2.0 
mg/dl or less. creatinine level of at least 2.0 mg/dl, platelet 
count of at least 75.000 cells/mm 3.white blood cell count 
of more than 2500 cells/mm 3. age older than 18 years, 
performance status of less than 2 (Eastern Cooperative 
Oncology Group), and signed informed consent. Exclu- 
sion criteria included distant metastatic disease, previous 
chemotherapy, previous radiotherapy, uncontrolled infec- 
tion. T1N0 lesions, and bulky disease not encompassable 
by a safe radiation port. Forty patients were entered into 
this trial. Thirty-seven others were deemed ineligible for 
the following reasons: distant metastases, nine; required 
radiation port too large, eight; medical comorbidities. 
seven; unresectability, four; patient refusal, four; previous 
cancer treatment, hree: and T1N0 lesion, two. The study 
was approved by the Human Studies Committee. and 
written informed consent was obtained from all partici- 
pants. 
Staging, All patients underwent screening for distant 
metastatic disease, with a computed tomographic scan of 
the chest, upper abdomen and brain along with a bone 
scan. Esophagoscopy with endoscopic ulirasonography 
was performed to assess the local extent of the tumor. The 
tumor stage was defined according to the classification of
the American Joint Committee on Cancer. 6
Chemotherapy. Chemotherapy consisted of two 
courses of cisplatin, 5-fluorouracil, and paclitaxel 4 weeks 
apart. Cisplatin [20 mg/m 2) was infused for 1 hour on days 
i to 5 The 5-fiuorouracil (800 mg/ma/da~ I was given as a 
continuous infusion on days 1 to 5. Paclitaxel was given for 
3 hours according to a dose escalation schema (75, 125, 
and 100 mg/m2). Fig. 1 illustrates the treatment schema. 
Paclitaxel at 75 mg/m 2 was chosen empirically. Initially, 
only three patients were to be treated at this level, but a 
stroke and paclitaxel anaphylaxis occurred in patients 2 
and 3, prohibiting accurate assessment of toxicity. Accord- 
ingly, three additional patients were treated at this dose 
level. The dose was then escalated to 125 mg/m 2 (again 
empirically chosen), and three patients were treated. A 
myocardial infarction thought to be related to the 5- 
fluorouracil developed in the third patient (with known 
coronary disease) during the first cycle of treatment. The 
second cycle was therefore omitted. Accordingly, one 
additional patient was treated at this dose level. We 
determined that paclitaxel at 125 mg/m 2was greater than 
the maximum tolerated ose (75% grade 4 toxicity; one 
myocardial infarction and fever and neutropenia in two 
patients) and chose 100 mg/m 2 as the next dose level. The 
first three patients treated with paclitaxe! at 100 mg/m 2
tolerated chemotherapy well, without neutropenia or 
other significant complications. 
Radiation therapy. This study employed a concurrent 
boost technique in which the initial volume (gross tumor 
and elective volume) was treated once a day and the boost 
volume (gross tumor) was also given a concurrent boost 
for 10 days on a twice daily schedule. A total dose of 45 Gy 
was delivered in 25 fractions through 5 weeks (180 cGy/ 
fraction) to the original volume. An additional dose of 
13.5 Gy was given in 10 fractions by delivering 135 cGy in 
the morning on the first of the twice-daily treatment 
schedule for the first 5 days and last 5 days to the gross 
tumor during continuous 5-fluorouracil infusion. The 
gross tumor therefore received 58.5 Gy and was in the 
field that was tO be resected. The area of esophagus that 
was to be anastomosed to the stomach received 45 Gy, 
which was thought o be a "safe" dose to allow healing. 
This intensive dose was chosen to maximize the chance for 
a complete resection and complete response. 
Surgery. After induction treatment, patients were 
restaged with a computed tomographic scan of the chest 
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Table I. Complications of chemotherapy according to paclitaxel dose 
75 mg/m 2 (n = 6) 125 mg/m 2 (n = 4) 
Cycle Complication No. % No. % 
100 mg/m 2 (n = 30) 
No. % 
Nadir ANC 1477 790 1370 
GF 2/6 33 2/4 50 6/28 21 
G4E 0 3/4 75 12/28 43 
Nadir ANC 847 1200 1036 
GF 2/6 33 1/2 50 7/28 25 
G4E 3/6 50 2/2 100 16/28 57 
ANC, Absolute neutrophil count; GF, granulocytopenic fever; G4E, esophagitis necessitating enteral or parenteral nutrition. 
Table II. Influence of chemotherapy dose reduction 
on pathologic complet e response rate 
/~CR 
No. % p Value 
Complete Chemotherapy 12/24 50 0.076 
Reduced chemotherapy 2/12 17 
PCR, Pathologic omplete response. 
Table III. Influence of histology on pathologi c 
complete response rate 
PCR 
Histology No. % p Value 
Squamous cell carcinoma 4/6 67 
0.18 
Adenocarcinoma 10/30 33 
PCR, Pathologic complete response. 
and upper abdomen. Resection was undertaken if there 
was no evidence of unresectability on the restaging 
scan. Resection was planned for day 62 but was delayed 
if necessary to allow the patient o recover sufficiently 
from induction treatment. A left thoracoabdominal 
approach was generally used for low-lying lesions, and 
an Ivor Lewis approach was used for higher lesions. 
Statistical methods. Survival was measured from the 
date of first therapy to the date of death or most recent 
follow-up visit. Actuarial survival was calculated with the 
Kaplan-Meier method. Fisher's Exact Test was used to 
determine whether a relationship existed between two 
nominal variables. 
Results 
Forty patients were entered into this trial, 35 men 
and five women. Thirty-eight patients were white 
and two were black. The mean age was 62 (33 
through 76) years, and 10 patients were 70 years old 
or older. Thirty-two patients (80%) had adenocar- 
cinoma, seven (17.5%) had squamous cell carci- 
noma. and one (2.5%) had an undifferentiated 
tumor. Twenty-six patients had Barrett's mucosa. 
Before treatment, he patients' tumors were staged 
as follows: 12 were T2N0. three were T2N1, 16 were 
T3N0. eight were T3N1, and one was T4N0. Thus 28 
of 40 patients (70%) had locally advanced esopha- 
geal cancer (T3. or stage liB or greater). 
The induction program was rigorous and relatively 
toxic. Most patients required nutritional support to 
complete this protocol. The average length of stay 
related to the induction treatment was 17 (8 to 50) 
days. A 10-day period was required for completion of 
both cycles of chemotherapy, so on average 7 addi- 
tional hospital days were required to deal with side 
effects or complications of therapy, The complications 
of chemotherapy according to the dose of paclitaxel 
are listed in Table I. A dose of 100 mg/m 2was chosen 
to continue the phase II study on the basis of accePt- 
able levels of toxicity. Other complications of induc- 
tion treatment included pneumonia (four cases), ana- 
phylactic reaction to paclitaxel (two cases), myocardial 
infarction (two cases), line sepsis (two cases), subcla- 
vian vein thrombosis (two cases), pericarditis (one 
case), empyema (one case), stroke (one case), and 
toxic colitis (one case). Four patients were no longer 
eligible for operation as a result of toxicity in three 
cases and disease progression (liver metastasis) in the 
other. Two patients died during induction therapy, one 
of severe pneumonia nd the other of myocardial 
infarction. Thirteen of 40 Patients (33%) required 
chemotherapy dose reduction. Nine patients had dose 
reductions, in response to esophagitis in five cases and 
hematologic toxicity in four. Four patients had only 
one cycle of chemotherapy because of pneumonia in 
one case, toxic colitis in one, paclitaxel anaphylactic 
reaction in one, and a myocardial infarction in the 
fourth. All patients completed radiation therapy. 
Thirty-six patients (90%) underwent resection an 
average of 77 days after the initiation of treatment. 
Twenty patients had a left thorocoabdominal p- 
proach, 14 had an Ivor Lewis approach, and two 
underwent ranshiatal esophagectomy. Complica- 
tions developed in six patients (17%): chyloth0rax in
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Fig. 2. Kaplan-Meier survival curve for all 40 patients 
registered in the study. 
one, adult respiratory distress yndrome in two, aorto- 
gastric fistula in one, stomach necrosis in one, delirium 
in one, and respiratory failure in one. Both patients 
with adult respiratory distress yndrome died, one of 
multiorgan failure and one of an aortogastric fistula. 
The average l ngth of stay after esophagectomy was 22 
(range 7 to 72, median 10) days. Total treatment- 
related mortality was 10% (4/40). 
Fourteen of 36 patients had no tumor present in 
the resected specimen, for a pathologic omplete 
response rate of 39%. Fifteen of 36 patients (42%) 
had no tumor in the resected esophagus. Twenty- 
four of 36 patients (67%) had no tumor in the 
resected lymph nodes. The postsurgical staging was 
as follows: TON0, 14; TON1, one; TIN0, four; T1N1, 
one; T2N0, three; T2N1, four; T3N0, three; and 
T3N1, six. Twenty-four of 36 patients (67%) were in 
lower stages than before treatment. The pathologic 
complete response rates were 33%, 50%, and 38% 
at paclitaxel doses of 75, 125, and 100 mg/m 2, 
respectively. Patients who were able to tolerate the 
complete chemotherapy regimen had a higher com- 
plete response rate than did those who required 
dose reduction (p = 0.076; Table II). There was a 
trend (p = 0.18) toward a higher pathologic om- 
plete response rate among patients who had squa- 
mous cell carcinoma than among those who had 
adenocarcinoma (Table III). All the patients with 
squamous cell cancer had locally advanced isease 
(T3 or stage IIB or greater), and four of six required 
chemotherapy dose reduction. Accordingly, the 
prognostic variables of stage and chemotherapy 
completion did not explain the trend toward an 
Table IV. Survival and complete response rates with 
induction chemoradiotherapy for esophageal cancer 
First author 
Treatment- % 
No. of PCR related 
Year patients (%) mortality (%) 1 yr 2yr 
Walsh 2 1996 58 25 9 52 37 
Forastiere 3 1993 43 24 7 70 61 
Wright (current 1997 40 39 10 81 61 
report) 
PCR, Pathologic omplete response rate. 
increased response rate among patients with squa- 
mous cell cancer. 
Nine patients died during this study: four of 
treatment complications, three of progression of 
disease (liver metastases in three, peritoneum in 
one, and low periaortic nodes in one), one of 
respiratory failure more than a year after treatment, 
and one of a late myocardial infarction. Of the three 
patients who died of esophageal cancer after treat- 
ment, one had disease progression during induction 
treatment (liver and peritoneum), one had a patho- 
logic complete response (T3N1 to TON0), and one 
had an incomplete response (T3N1 to TON!). A 
preliminary Kaplan-Meier survival curve is depicted 
in Fig. 2. The 1-year survival rate was 81% (95% CI 
68% to 95%), and the 2-year survival rate was 61% 
(95% CI 35% to 86%). The median follow-up is 11.9 
months. The mean cost of treatment per patient was 
$50,209 dollars ($31,446 to $109,621). The mean 
hospital cost related to induction chemotherapy and 
radiotherapy was $23,091 dollars ($14,810 to 
$52,487). The mean hospital cost for esophagectomy 
was $24,989 ($15,338 to $85,639). 
Discussion 
This phase I and II trial of induction chemoradio- 
therapy demonstrated that the maximum tolerated 
dose of paclitaxel was 100 mg/m 2. This was an 
intense regimen, though, with some toxicity devel- 
oping in most patients. Esophagitis necessitating 
nutritional support was the most common toxic 
effect, occurring in all patients at 125 mg/m 2 pacli- 
taxel and in 57% of patients at 100 mg/m 2. Hema- 
tologic toxicity was uncommon. Pneumonia devel- 
oped in four patients, probably as a result of 
dysphagia-induced microaspiration and depressed 
immunity from chemoradiotherapy. Adult respira- 
tory distress yndrome occurred in two patients after 
esophagectomy, which has been rare in our experi- 
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ence in patients treated with resection alone or with 
chemotherapy followed by resection. Myocardial 
infarction developed in four patients, in two during 
induction treatment and in two after completion of 
all treatment. These patients had a history of stable 
coronary disease, but the issue of possible initiation 
of an unstable pattern by induction chemoradio- 
therapy must be raised, s The total treatment-related 
mortality rate was 10%, which is similar to other 
reports of induction chemoradiotherapy but higher 
than among patients who undergo resection 
only.2, 3, 9 The decline in quality of life, length of 
hospital stay (average 17 days), and cost during 
induction therapy are significant and must be 
weighed against possible enhanced long-term sur- 
vival. Although our median length of stay after 
esophagectomy was only 10 days, our mean stay was 
22 days, reflecting several outliers with severe com- 
plications. This increased length of stay reflects the 
toxicity of this program and is in contradistinction to 
our previous reports, in which the addition of che- 
motherapy alone did not affect length of stay. 9Only 
the significant prolongation of survival will make 
these costs worth bearing. 
This trial of an intensive induction program with 
paclitaxel and high-dose hyperfractionated radio- 
therapy resulted in a high (39%) complete response 
rate. Response rates were higher among patients 
with squamous cell carcinoma nd patients who had 
the complete course of chemotherapy, ashas been 
reported before. 2' 3, 7 The three deaths of recurrent 
disease were all related to distant metastases, ug- 
gesting good local control with this regimen. Al- 
though the follow-up period has been short, the 
2-year survival rate of 61% (95% CI 35% to 86%) is 
encouraging. Obviously, additional observation will 
be required to determine whether patients are cured 
or the appearance of metastases has just been 
delayed. The entry criteria were meant to be rela- 
tively inclusive, to allow treatment of the broad 
spectrum of patients with esophageal cancer who so 
often have comorbid disease. The patients in this 
study are typical of modern North American series: 
80% of patients with adenocarcinomas, 65% with 
Barrett's mucosa, and 70% with locally advanced 
tumors. The toxicity incurred in achieving these 
results is substantial and will only bear scrutiny if 
marked prolongation of survival occurs. 
The high (39%) pathologic complete response 
rate achieved compares favorably with other reports 
(Table IV). Our data are preliminary, and further 
follow-up will be necessary to see whether the 
remissions are durable. This regimen is too toxic for 
the majority of patients and should not be general- 
ized for application to most. Stricter entrance crite- 
ria for age, performance status, pulmonary disease, 
and cardiac disease would likely lead to less toxicity. 
It is also likely that starting enteral nutritional 
support before therapy would be of benefit. The 
relatively large dose of radiation for an induction 
program (58.5 Gy to the tumor and 45 Gy to the 
mediastinum, where the esophageal nastomosis  
made) probably contributed to the complications 
and will have to be reduced. The relative influence 
of chemotherapy versus radiotherapy on the com- 
plete response rate is unknown. Ix~cal control has 
been excellent with induction chemoradiotherapy, 
and distant metastasis has been the primary reason 
for relapse. More efficacious systemic therapies 
(e.g., with paclitaxel), rather than more intense 
radiotherapy strategies, should therefore be pur- 
sued. We plan to investigate another egimen with 
the same dose of paclitaxel (100 mg/m2), a reduced 
dose of 5-fluorouracil, carboplatin, and a reduced 
amount of radiotherapy (40 Gy). 
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Discussion 
Dr. Michael E. Burt (New York, N.Y). I congratulate 
you for carrying out a well-designed and implemented 
phase I and II trial of intensive induction chemoradio- 
therapy in esophageal carcinoma. As presented, this was 
an extremely intensive regimen, with subsequent high 
morbidity and an increased mortality rate. More than 50% 
of the patients had severe esophagitis, and other morbid- 
ities occurred in 40%. This led to a chemotherapy dose 
reduction in 33% of the patients, with subsequent de- 
creased tumor response and delays in the planned oper- 
ation. Despite the high morbidity of this induction regi- 
men, however, 39% of the resected patients had a 
complete pathologic response. This is slightly higher than 
the 28% response reported by Dr. Orringer's group and 
the 25% reported by Dr. Walsh's group. 
I have three interrelated questions. Because chemo- 
therapy and radiation therapy alone in randomized trials 
have been reported to carry a 25% 5-year survival rate, 
and your trial reported a 39% complete response to 
induction chemoradiotherapy, what do you consider the 
role of surgery to be in localized esophageal carcinoma 
after chemotherapy and radiation therapy? Also, in future 
trials are you looking at the role of newer modalities, such 
as positron emission tomographic scanning, to predict a 
complete response? And what is the role of surgery for 
those patients? 
Dr. Carolyn E. Reed (Charleston, S.C.). At the Medical 
University of South Carolina, we have used two cycles of 
paclitaxel (Taxol), cisplatin, and 5-fluorouracil alone as 
induction therapy in 20 patients, all in stage Ill. Our Taxol 
dose was 250 mg/m 2. Our pathologic omplete response 
rate was 15%. Clearly, radiation therapy is adding signif- 
icantly to the pathologic omplete response rate, as has 
been shown in other phase II and III studies. However, 
other studies have shown that adding radiation therapy to 
a three-drug regimen substantially increases morbidity. 
I have two questions. First, why did you choose hyper- 
fractionated radiotherapy, which in a rural setting is either 
not feasible or extremely expensive? Second, was pulmo- 
nary toxicity a concern, and is that one of the reasons you 
used a lower Taxol dose? Would you consider using two 
drugs with radiation therapy in a multiinstitutional set- 
ting? If so, which two drugs? 
Dr. Nasser K. Altorki (New York, N.Y). I congratulate 
you on undertaking a fairly brave regimen before esoph- 
ageal resection and yet accomplishing it with the usually 
excellent results that we are accustomed to from the 
Massachusetts General group. Some of my concerns have 
been already echoed by Dr. Reed. You noted in your 
presentation that the esophagus was quite edematous at 
the time of the operation. Would you comment on 
whether that has affected the anastomotic complication 
rate, which is usually exceedingly ow from the Massachu- 
setts General Hospital? 
Dr. Wright. To address Dr. Burt first, with respect o 
the role of surgery after induction treatment, previous 
reports from our hospital indicate that even with endo- 
scopic ultrasonography wehave unable to predict a com- 
plete response after induction chemotherapy or chemora- 
diotherapy. Accordingly, surgery still has a role in these 
cases. Indeed, despite this intense regimen, 60% of pa- 
tients had residual disease that was resected. Whether 
there will be long-term survivors among those who have 
resected residual disease remains to be seen, but For- 
astier's data from Michigan do indicate that patients 
undergoing resection of persistent disease do have a 
meaningful five-year survival. We have investigated 
positron emission tomographic scanning in lung cancer, 
especially in patients with N2 disease who undergo induc- 
tion chemoradiotherapy, butwe have not yet begun this in 
esophageal cancer. 
To address Dr. Reed's questions, why hyperfraction- 
ated radiotherapy twice daily? In part it was because our 
radiation therapist, Dr. Choi, has had a long-standing 
interest in pursuing this avenue. We realize it is not 
available in most hospitals, but we wanted to create a 
program that was maximally intense and see what we 
could achieve. Obviously, to some extent we paid the price 
for that. I do think that some of our pulmonary toxicity 
was caused by the radiation, and the radiation dose needs 
to be significantly reduced. 
I think we are still going to be firmly committed to three 
drugs, but with a much smaller dose of radiation therapy 
to allow us to give the drugs in larger doses. This should 
control distant micrometastatic disease. 
Last, regarding our anastomotic complication rate, we 
had one late fistula after a patient was on a ventilator for 
a month with adult respiratory distress syndrome. This 
fistula subsequently eroded into the aorta, so we had an 
anastomotic complication rate of 2.5%, which is accept- 
able for such an intense induction program. 
